Logo
x

Search

Subscribe Now

Us FDA

Rigel’s R289 Secures the US FDA’s Fast Track Designation for Treating Lower-Risk Myelodysplastic Syndrome

Rigel’s R289 Secures the US FDA’s Fast Track Designation for Treating Lower-Risk Myelodysplastic Syndrome

  • December 3, 2024
Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy

Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy

  • November 7, 2024
ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)

ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)

  • November 7, 2024
Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dog...

  • November 7, 2024
Insights+: The US FDA New Drug Approvals in July 2024

Insights+: The US FDA New Drug Approvals in July 2024

  • August 13, 2024
Insights+: The US FDA New Drug Approvals in June 2024

Insights+: The US FDA New Drug Approvals in June 2024

  • July 16, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.